Search / Trial NCT06228001

Holter of Movement in Patients With Amyotrophic Lateral Sclerosis.

Launched by LAURENT SERVAIS · Jan 18, 2024

Trial Information

Current as of December 21, 2024

Recruiting

Keywords

Actimyo Accelerometry Daily Living

ClinConnect Summary

The clinical trial titled "Holter of Movement in Patients With Amyotrophic Lateral Sclerosis" is studying how movement in patients with amyotrophic lateral sclerosis (ALS) can be monitored over time. ALS is a progressive disease that affects the nerves and muscles, making it harder for people to move. In this study, researchers want to include about 30 patients who have a confirmed diagnosis of ALS. To be eligible, participants need to be over 18 years old, be stable on their medication (if taking Riluzole), and be able to understand the study tasks.

Participants will visit the study site every three months for a year, where doctors will assess their condition. After each visit, participants will wear a special device called Actimyo for one month, which tracks their movements throughout the day. This study is still looking for volunteers, so if you or someone you know is interested, it’s important to understand the eligibility criteria and that participants should not have significant cognitive issues or recent surgeries that could affect their movement.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Clinically defined or probable diagnosis of ALS according to El Escorial criteria revised with Awaji's electro-diagnostic algorithm.
  • Over 18 years old.
  • Signed informed consent
  • If patient on Riluzole, the dosage should be stable for 1 month and continued throughout the study period.
  • Exclusion Criteria:
  • Patients with excessive cognitive disorders, limiting the understanding of task or with apparent communication difficulties hindering data collection.
  • Any other previous or present pathology having an impact on motor function.
  • Recent surgery or trauma (less than 6 months) in the upper or lower limbs.
  • Prior neurological, endocrine, infectious, allergic, or chronic or acute inflammatory pathology in the three weeks preceding inclusion.
  • Patients participating in an interventional clinical trial.

Trial Officials

Stéphanie Delstanche, MD

Principal Investigator

Centre de référence des maladies neuromusculaire, Centre Hospitalier Régional de la Citadelle

About Laurent Servais

Laurent Servais is a prominent clinical trial sponsor dedicated to advancing medical research through innovative and rigorous study designs. With a focus on neuromuscular disorders, the organization collaborates with leading researchers and institutions to develop effective therapies that improve patient outcomes. Committed to ethical standards and regulatory compliance, Laurent Servais prioritizes transparency and patient safety in all clinical endeavors, fostering an environment of collaboration and scientific excellence. Through its strategic initiatives, the sponsor aims to contribute significantly to the understanding and treatment of rare diseases, ultimately enhancing the quality of life for affected individuals.

Locations

Liège, , Belgium

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0